Professor Emeritus of Addiction Medicine, Hannu Alho (University of Helsinki, Finland) discusses the need for effective treatment options to manage alcohol use disorder, focusing on odansetron as a newly emerging possibility. Ondansetron is a specific 5HT3-receptor antagonist, which blocks 5HT3 receptors in the gastrointestinal tract and central nervous system, and has been used since the early 90s as an effective antiemetic in the prevention of chemo- and radiotherapy-induced nausea and vomiting. Here, Prof. Alho considers the rationale for its use in alcohol use disorder, the genetic segmentation approach, design and clinical data so far from the currently recruiting ONWARD study (ClinicalTrials.gov Identifier: NCT04101227), and how this potential therapy could fit into clinical practice.
Questions
1. How is ondansetron likely to fit into the treatment paradigm for alcohol use disorder? (0:08)
2. Has COVID-19 had an impact on alcohol use disorder? (4:22)
See also the 1st part of this interview: Hannu Alho – Potential of Ondansetron in Alcohol Use Disorder (Part 1)
Disclosures: Prof. Alho is the coordinating principal investigator of the ONWARD trial sponsored by Adial Pharmaceuticals.
Support: Interview commissioned and filming supported by Touch Medical Media. However, a company representative from Adial Pharmaceuticals did review this independent video interview prior to publication.
